Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The study is a multicenter, open label Phase I/II trial.
1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in
combination with venetoclax and azacitidine for patients with CD33 positive AML. (Phase
I portion)
2. To assess the percentage of patients with CR, CRh, CRi, MLFS or Overall Response (CR +
CRh + CRi + MLFS), up to 6 months after the start of treatment without receiving other
AML therapies.. (Phase 2 portion)